Vivos Inc.

Equities

RDGL

US92858K2042

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 15:59:55 2024-05-15 EDT			5-day change	1st Jan Change
0.1999 ^USD	-0.47%		+18.99%	+176.49%

05-09	Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

July 25, 2022 at 07:17 am

Vivos Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.0105 million. Net loss was USD 0.787538 million compared to USD 1.86 million a year ago.
For the six months, sales was USD 0.0235 million. Net loss was USD 1.49 million compared to USD 2.15 million a year ago.

Latest news about Vivos Inc.

Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Vivos Inc. Announces Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation	12-20	CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Vivos Inc. Auditor Raises 'Going Concern' Doubt	23-02-28	CI
Vivos Inc Files A New Patent on Alternate Particles for Precision Radionuclide Therapy	23-01-11	CI
Vivos Inc. Files New Patent on Precision Radionuclide Therapy Support System Equipment	23-01-03	CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-19	CI
Vivos Inc. Files A New Patent on the Hydrogel Component of Isopet®/Radiogel™	22-09-14	CI
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy	22-08-16	CI
Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-25	CI
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-07	CI
Vivos Inc. Auditor Raises 'Going Concern' Doubt	22-03-06	CI
Vivos Inc. Files Its Particle Patent in Several Countries	22-02-24	CI
Vivos Inc. Obtains Feedback from the FDA on Clinical Testing of RadioGel?	21-12-02	CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-25	CI
Vivos Inc Signs A Memorandum of Understanding for A New Regional Clinic in Ny for Isopet Therapy	21-10-18	CI
Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel™	21-09-20	CI
Vivos Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-02	CI
Vivos Inc Initiates Isopet® Therapy in Horses	21-06-24	CI
Vivos Inc Enhances Radiogel™ Manufacturing Process	21-05-24	CI

Chart Vivos Inc.

Duration

Period

More charts

Company Profile

Vivos Inc. is a radiation oncology medical device company. The Company is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. It is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Companyâs IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The Company is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Medical Imaging Systems

	1st Jan change	Capi.
VIVOS INC.	+176.49%	77.94M
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.	-2.78%	15.11B
IRAY TECHNOLOGY COMPANY LIMITED	-37.28%	2.88B
SONOSCAPE MEDICAL CORP.	-12.11%	2.48B
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.	-14.23%	1.43B
CORETAG, INC.	-.--%	1.12B
NANO-X IMAGING LTD.	+66.72%	614M
GUERBET	+90.77%	509M
DETECTION TECHNOLOGY OYJ	+18.98%	260M
DRTECH CORPORATION	-2.35%	227M

Medical Imaging Systems